Symptom-driven lorazepam protocol for treatment of severe alcohol withdrawal delirium in the intensive care unit

Pharmacotherapy

Volumn 27, Issue 4, 2007, Pages 510-518

  DeCarolis, Douglas D ^a   Rice, Kathryn L ^a   Ho, Libin ^b   Willenbring, Mark L ^c   Cassaro, Susan ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b HEALTHPARTNERS INSTITUTE   (United States)

^c NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM   (United States)

Author keywords

Alcohol withdrawal delirium; Alcohol withdrawal syndrome; AWD; Benzodiazepine; Intensive care; Lorazepam; Midazolam; Treatment protocol

Indexed keywords

ALANINE AMINOTRANSFERASE; ALCOHOL; ASPARTATE AMINOTRANSFERASE; BENZODIAZEPINE DERIVATIVE; CLONIDINE; HALOPERIDOL; LORAZEPAM; MIDAZOLAM; THIAMINE;

ADULT; AGITATION; ALCOHOL WITHDRAWAL; ARTICLE; ASPIRATION PNEUMONIA; CLINICAL ARTICLE; CLINICAL PROTOCOL; CONTINUOUS INFUSION; DELIRIUM; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; DRUG INTERMITTENT THERAPY; FEMALE; HALLUCINATION; HEART INFARCTION; HUMAN; HYPOTENSION; INTENSIVE CARE PSYCHOSIS; LENGTH OF STAY; MALE; ORIENTATION; OUTCOMES RESEARCH; PATIENT MONITORING; PROPYLENE GLYCOL TOXICITY; RETROSPECTIVE STUDY; SWEATING; SYMPTOMATOLOGY; TREATMENT OUTCOME; TREMOR;

ALCOHOL WITHDRAWAL DELIRIUM; ANTI-ANXIETY AGENTS; BENZODIAZEPINES; CLINICAL PROTOCOLS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HALF-LIFE; HOSPITALIZATION; HOSPITALS, VETERANS; HUMANS; INFUSIONS, INTRAVENOUS; INJECTIONS, INTRAVENOUS; INTENSIVE CARE UNITS; LENGTH OF STAY; LORAZEPAM; MALE; MIDAZOLAM; MIDDLE AGED; PROPANOLAMINES; QUESTIONNAIRES; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 34047200018     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.27.4.510     Document Type: Article

References (43)

1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4th ed. Washington, DC: American Psychiatric Association; 1994.
2. Victor M, Adams RD. The effect of alcohol on the nervous system. Res Publ Assoc Res Nerv Ment Dis 1953;32:526-73.
3. Ferguson JA, Suelzer CJ, Eckert GJ, Zhou XH, Dittus RS. Risk factors for delirium tremens development. J Gen Intern Med 1996;11:410-14.
4. Cushman P Jr. Delirium tremens: update on an old disorder. Postgrad Med 1987;82:117-22.
5. Mayo-Smith MF, Beecher LH, Fischer TL, et al. Management of alcohol withdrawal delirium, an evidence-based practice guideline. Arch Intern Med 2004;164:1405-12.
6. Lineaweaver WC, Anderson K, Hing DN. Massive doses of midazolam infusion for delirium tremens without respiratory depression. Crit Care Med 1988;16:294-5.
7. Nolop KB, Natow A. Unprecedented sedative requirements during delirium tremens. Crit Care Med 1985;13:246-7.
8. Woo E, Greenblatt DJ. Massive benzodiazepine requirements during acute alcohol withdrawal. Am J Psychiatry 1979;136:821-3.
9. Wolf KM, Shaughnessy AF, Middleton DB. Prolonged delirium tremens requiring massive doses of medication. J Am Board Fam Pract 1993;6:502-4.
10. Coomes TR, Smith SW. Successful use of propofol in refractory delirium tremens. Ann Emerg Med 1997;30:825-8.
11. McCowan C, Marik P. Refractory delirium tremens treated with propofol: a case series. Crit Care Med 2000;28:1781-4.
12. Takeshita J. Use of propofol for alcohol withdrawal delirium: a case report. J Clin Psychiatry 2004;64:134-5.
13. Daeppen JB, Gache P, Landry U, et al. Symptom-triggered vs fixed-schedule doses of benzodiazepine for alcohol withdrawal: a randomized treatment trial. Arch Intern Med 2002;162:1117-21.
14. Jaeger TM, Lohr RH, Pankratz VS. Symptom-triggered therapy for alcohol withdrawal syndrome in medical inpatients. Mayo Clin Proc 2001;76:695-701.
15. Saitz R, Mayo-Smith MF, Roberts MS, Redmond HA, Bernard DR, Calkins DR. Individualized treatment for alcohol withdrawal: a randomized double-blind controlled trial. JAMA 1994;272:519-23.
16. Foy A, Kay J, Taylor A. The course of alcohol withdrawal in a general hospital. Q J Med 1997;90:253-61.
17. Newman JP, Terris DJ, Moore M. Trends in the management of alcohol withdrawal syndrome. Laryngoscope 1995;105:1-7.
18. Sellers EM. Alcohol withdrawal severity is decreased by symptom-oriented adjusted bolus therapy in the ICU. Intensive Care Med 2003;29:2230-8.
19. Mayo-Smith MF, for the American Society of Addiction Medicine. Pharmacological management of alcohol withdrawal: a meta-analysis and evidence-based practice guideline. JAMA 1997;278:144-51.
20. Holbrook AM, Crowther R, Lotter, A, Cheng C, King D. Meta-analysis of benzodiazepine use in the treatment of acute alcohol withdrawal. Can Med Assoc J 1999;160:649-55.
21. Lejoyeux M, Solomon J, Ades J. Benzodiazepine treatment for alcohol-dependent patients. Alcohol Alcohol 1998;33:563-75.
22. Lohr RH. Treatment of alcohol withdrawal in hospitalized patients. Mayo Clin Proc 1995;70:777-82.
23. Erwin WE, Williams DB, Speir WA. Delirium tremens. South Med J 1998;91:425-32.
24. Sullivan JT, Sykora K, Schneiderman J, Naranjo CA, Sellers EM. Assessment of alcohol withdrawal: the revised clinical institute withdrawal assessment for alcohol scale (CIWA-Ar). Br J Addict 1989;84:1353-7.
25. Bayard M, McIntyre J, Hill KR, Woodside J Jr. Alcohol withdrawal syndrome. Am Fam Physician 2004;69:1443-550.
26. DeBellis R, Smith BS, Choi S, Malloy M. Management of delirium tremens. J Intensive Care Med 2005;20:164-73.
27. Rabinowitz T. Delirium: an important (but often unrecognized) clinical syndrome. Curr Psychiatry Rep 2002;4:202-8.
28. Mirafzali S. Alcohol withdrawal delirium [letter]. Arch Intern Med 2005;165:586.
29. Hersh D, Kranzler HR, Meyer RE. Persistent delirium following cessation of heavy alcohol consumption: diagnostic and treatment options. Am J Psychiatry 1997;154:846-51.
30. Mayo-Smith MF. Treatment of delirium tremens-reply [letter]. Arch Intern Med 2005;165:587.
31. Cutshall B. The Saunders-Sutton syndrome: an analysis of delirium tremens. Q J Stud Alcohol 1965;25:423-48.
32. Stendig-Lindberg G, Rudy N. Stepwise regression analysis of an intensive 1-year study of delirium tremens. Acta Psychiatr Scand 1980;62:273-97.
33. Miller FT. Protracted alcohol withdrawal delirium. J Subst Abuse Treat 1994;11:127-30.
34. Ellenhorn MJ, Barceloux DG. Alcohols and glycols. In: Medical toxicology. New York: Elsevier, 1988:809-10.
35. Arbour RB. Propylene glycol toxicity related to high-dose lorazepam infusion: case report and discussion. Am J Crit Care 1999;8:499-506.
36. D'Ambrosio JA, Borchardt-Phelps P, Nolen JG, Cerra FB. Propylene glycol-induced lactic acidosis secondary to a continuous infusion of lorazepam [abstract]. Pharmacotherapy 1993;13:274.
37. Cawley MJ. Short-term lorazepam infusion and concern for propylene glycol toxicity: case report and review. Pharmacotherapy 2001;21:1140-4.
38. Tayar J, Jabbour G, Saggi SJ. Severe hyperosmolar metabolic acidosis due to a large dose of intravenous lorazepam [letter]. N Engl J Med 2002;346:1253-4.
39. Seay RE, Graves PJ, Wilkin MK. Comment: possible toxicity from propylene glycol in lorazepam infusion [letter]. Ann Pharmacother 1997;31:647-8.
40. Arbour R, Esparis B. Osmolar gap metabolic acidosis in a 60-year-old man treated for hypoxemic respiratory failure. Chest 2000:118:545-6.
41. Reynolds HN, Teiken P, Regan ME, et al. Hyperlactatemia, increased osmolar gap, and renal dysfunction during continuous lorazepam infusion. Crit Care Med 2000;28:1631-4.
42. Parker MG, Fraser GL, Watson DM, Riker RR. Removal of propylene glycol and correction of increased osmolar gap by hemodialysis in a patient on high-dose lorazepam infusion therapy. Intensive Care Med 2002;28:81-4.
43. Chicella M, Jansen P, Parthiban A, et al. Propylene glycol accumulation associated with continuous infusion of lorazepam in pediatric intensive care patients. Crit Care Med 2002;30:2752-6.